The Kelly Gynecologic Oncology Service, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Greater Baltimore Medical Center, Towson, MD, USA.
Gynecol Oncol. 2020 May;157(2):469-475. doi: 10.1016/j.ygyno.2020.01.041. Epub 2020 Feb 12.
To evaluate the effects of an enhanced recovery after minimally invasive surgery (MIS-ERAS) protocol on opioid requirements and post-operative pain in patients undergoing minimally invasive hysterectomy on a gynecologic oncology service.
For this retrospective study, opioid use (oral morphine equivalents (OME)) and post-operative pain scores were compared between patients undergoing minimally invasive hysterectomy pre and post MIS-ERAS protocol implementation. Patients with chronic opioid use or chronic pain were excluded. Opioid use and pain scores were compared between groups using Wilcoxon Rank Sum, Student's t-test, and multiple linear regression. Compliance and factors associated with opioid use and pain scores were assessed.
The MIS-ERAS cohort (n = 127) was compared to the historical cohort (n = 99) with no differences in patient demographic, clinical or surgical characteristics observed between groups. Median intra-operative and inpatient post-operative opioid use were lower among the MIS-ERAS cohort (12.0 vs 32.0 OME, p < .0001 and 20.0 vs 35.0 OME, p = .02, respectively). Pain scores among MIS-ERAS patients were also lower (mean 3.6 vs 4.1, p = .03). After controlling for age, BMI, operative time, length of stay, cancer diagnosis, and surgical approach, the MIS-ERAS cohort used 10.43 fewer OME intra-operatively (p < .001), 10.97 fewer OME post-operatively (p = .019) and reported pain scores 0.56 points lower than historical controls (p = .013). Compliance was ≥81% for multimodal analgesia elements and ≥75% overall.
Enhanced recovery after minimally invasive surgery protocol implementation is an effective means to reduce opioid use, both in the intra-operative and post-operative phases of care, among gynecologic oncology patients undergoing minimally invasive hysterectomy.
评估微创外科术后强化康复(MIS-ERAS)方案对妇科肿瘤患者行微创子宫切除术的阿片类药物需求和术后疼痛的影响。
在这项回顾性研究中,比较了妇科肿瘤服务中心实施 MIS-ERAS 方案前后接受微创子宫切除术患者的阿片类药物使用(口服吗啡等效物(OME))和术后疼痛评分。排除慢性阿片类药物使用者或慢性疼痛患者。使用 Wilcoxon 秩和检验、学生 t 检验和多元线性回归比较组间的阿片类药物使用和疼痛评分。评估了依从性以及与阿片类药物使用和疼痛评分相关的因素。
MIS-ERAS 队列(n=127)与历史队列(n=99)进行了比较,两组患者的人口统计学、临床或手术特征无差异。MIS-ERAS 队列的术中及住院期间术后阿片类药物使用中位数较低(12.0 vs 32.0 OME,p<0.0001 和 20.0 vs 35.0 OME,p=0.02)。MIS-ERAS 患者的疼痛评分也较低(平均 3.6 vs 4.1,p=0.03)。在校正年龄、BMI、手术时间、住院时间、癌症诊断和手术方式后,MIS-ERAS 队列术中使用 OME 减少了 10.43(p<0.001),术后减少了 10.97(p=0.019),疼痛评分比历史对照组低 0.56 分(p=0.013)。多模式镇痛要素的依从性≥81%,总体≥75%。
妇科肿瘤患者行微创子宫切除术时,实施微创外科术后强化康复方案是减少阿片类药物使用的有效方法,无论是在手术期间还是在术后护理期间。